Replies to post #71471 on Biotech Values

[dewophile]

ZGEN
"I assume the main reason for wanting to replace interferon therapy with a strictly oral small-molecule regimen is due to the side effects of interferon. Again, this may not be as much of an issue with IFN-Lambda given its potential for much improved tolerability compared to current interferon treatment."

it is conceivable that IN lambda will have a more favorable tolerability profile than some of the direct acting antivirals even factoring in the fact it is a weekly injection

re inform-1 - there will be data on early viral kinetics and tolerability, but there will be no readout on the bigger hurdle of viral breakthrough on longer treatment duration and most importantly relapse since every arm gets SOC after the initial protease/polymerase combo

lastly, even if/when all oral cocktails become standard, unless you think cure rates approach 100%, there is bound to be a role for interferon in refractory settings

[DewDiligence]

Albuferon has been discussed at great length on this board; since you’re a paid iHub member, you can use the Advanced Search tool to find everything that’s ever been posted about it.

Clearly, Albuferon is not a major advance from a scientific standpoint; however, its less frequent dosing relative to Pegasys and Pegintron does have the potential to improve compliance in the real world (as opposed to clinical-trial settings). All else being equal, better compliance ought to lead to a higher proportion of patients who achieve SVR.

Ditto the above for Locteron from Biolex.